News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM)

Al's Comment:

 This study shows a small improvement with Optune by itself compared to standard treatments.  Enough to show Optune does have a positive effect but not enough to use Optune by itself for recurrent Glioblastoma (or to use the standard treatments either).  Further study is needed combining Optune with other treatments to make meaningful gains in survival.


Posted on: 04/27/2020

EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM)

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740